Cross Country Healthcare (CCRN) Financials

$13.43 -0.10 (-0.74%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$13.44 +0.01 (+0.04%)

As of 04:05 AM Eastern

Annual Income Statements for Cross Country Healthcare

This table shows Cross Country Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-15	73	186
Consolidated Net Income / (Loss)	-15	73	186
Net Income / (Loss) Continuing Operations	-15	73	186
Total Pre-Tax Income	-16	103	253
Total Operating Income	-17	113	270
Total Gross Profit	1,323	2,005	2,794
Total Revenue	1,344	2,020	2,803
Operating Revenue	1,344	2,020	2,803
Total Cost of Revenue	21	15	9.61
Other Cost of Revenue	21	15	9.61
Total Operating Expenses	1,339	1,892	2,524
Selling, General & Admin Expense	233	300	324
Depreciation Expense	18	18	13
Other Operating Expenses / (Income)	1,076	1,570	2,180
Impairment Charge	2.89	0.72	5.60
Restructuring Charge	8.55	2.61	1.86
Total Other Income / (Expense), net	0.47	-9.90	-17
Interest Expense	2.19	9.82	18
Interest & Investment Income	2.05	0.00	0.00
Other Income / (Expense), net	0.61	-0.09	1.33
Income Tax Expense	-1.84	30	67
Basic Earnings per Share	($0.44)	$2.07	$5.02
Weighted Average Basic Shares Outstanding	33.38M	35.16M	37.01M
Diluted Earnings per Share	($0.44)	$2.05	$4.95
Weighted Average Diluted Shares Outstanding	33.38M	35.48M	37.54M
Weighted Average Basic & Diluted Shares Outstanding	32.81M	34.73M	36.82M

This table shows Cross Country Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-3.75	2.56	-16	2.69	9.04	13	21	29	36	35
Consolidated Net Income / (Loss)	-3.75	2.56	-16	2.69	9.04	13	21	29	36	35
Net Income / (Loss) Continuing Operations	-3.75	2.56	-16	2.69	9.04	13	21	29	36	35
Total Pre-Tax Income	-3.91	3.39	-20	3.69	13	20	30	40	43	49
Total Operating Income	-3.43	2.85	-19	2.92	13	20	35	44	48	52
Total Gross Profit	310	314	321	378	410	440	538	618	1,202	635
Total Revenue	310	315	340	379	414	442	541	623	625	636
Operating Revenue	310	315	340	379	414	442	541	623	625	636
Total Cost of Revenue	-0.23	1.51	19	1.29	4.17	2.36	3.13	4.91	-577	1.10
Other Cost of Revenue	-0.23	1.51	19	1.29	4.17	2.36	3.13	4.91	-	1.10
Total Operating Expenses	314	311	340	375	396	420	502	574	1,154	583
Selling, General & Admin Expense	56	54	60	63	68	70	79	84	81	81
Depreciation Expense	4.34	4.50	4.72	4.64	4.47	4.54	4.43	4.90	3.16	3.21
Other Operating Expenses / (Income)	247	251	273	306	324	345	418	484	1,070	493
Impairment Charge	2.17	0.00	0.11	0.60	-	0.19	0.53	0.00	-	3.86
Restructuring Charge	4.50	1.00	2.12	0.94	0.92	0.35	0.91	0.43	0.00	2.49
Total Other Income / (Expense), net	-0.48	0.54	-0.36	0.77	-0.54	-0.80	-4.88	-3.68	-5.12	-3.47
Interest Expense	0.61	0.55	0.57	0.46	0.59	0.67	4.87	3.69	5.33	3.50
Other Income / (Expense), net	-0.82	-0.02	0.21	1.23	0.05	-0.14	-0.01	0.01	0.21	0.03
Income Tax Expense	-0.16	0.83	-3.51	1.00	3.93	6.69	8.96	11	6.81	14
Basic Earnings per Share	($0.13)	$0.08	($0.47)	$0.08	$0.28	$0.37	$0.60	$0.82	$1.00	$0.94
Weighted Average Basic Shares Outstanding	33.38M	33.02M	33.96M	34.22M	35.16M	34.95M	35.35M	35.86M	37.01M	37.10M
Diluted Earnings per Share	($0.13)	$0.08	($0.47)	$0.08	$0.28	$0.36	$0.60	$0.81	$0.99	$0.93
Weighted Average Diluted Shares Outstanding	33.38M	33.06M	33.96M	34.60M	35.48M	35.15M	35.52M	36.56M	37.54M	37.49M
Weighted Average Basic & Diluted Shares Outstanding	32.81M	32.92M	33.81M	34.77M	34.73M	35.15M	35.80M	35.93M	36.82M	37.30M

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	65	13	2.57
Net Cash From Operating Activities	120	248	134
Net Cash From Continuing Operating Activities	120	248	134
Net Income / (Loss) Continuing Operations	-15	73	186
Consolidated Net Income / (Loss)	-15	73	186
Depreciation Expense	18	18	13
Non-Cash Adjustments To Reconcile Net Income	28	24	29
Changes in Operating Assets and Liabilities, net	88	133	-94
Net Cash From Investing Activities	-8.71	-14	-44
Net Cash From Continuing Investing Activities	-8.71	-14	-44
Purchase of Property, Plant & Equipment	-8.71	-14	-8.79
Acquisitions	0.00	0.00	-35
Other Investing Activities, net	0.00	0.20	0.09
Net Cash From Financing Activities	-47	-221	-88
Net Cash From Continuing Financing Activities	-47	-221	-88
Repayment of Debt	-18	-872	-1,740
Repurchase of Common Equity	-37	-58	-35
Issuance of Debt	18	721	1,700
Other Financing Activities, net	-9.54	-12	-13
Other Net Changes in Cash	-0.01	0.01	-0.01
Cash Interest Paid	1.37	7.53	13
Cash Income Taxes Paid	2.43	22	83

This table details how cash moves in and out of Cross Country Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	18	-5.58	64	-12	2.79	14	0.38	-3.31	-27	30
Net Cash From Operating Activities	24	7.47	82	6.01	12	70	119	47	4.32	141
Net Cash From Continuing Operating Activities	24	7.47	82	6.01	12	70	119	47	4.32	141
Net Income / (Loss) Continuing Operations	-3.75	2.56	-16	2.69	9.04	13	21	29	36	35
Consolidated Net Income / (Loss)	-3.75	2.56	-16	2.69	9.04	13	21	29	36	35
Depreciation Expense	4.34	4.50	4.72	4.64	4.47	4.54	4.43	4.90	3.16	3.21
Non-Cash Adjustments To Reconcile Net Income	2.34	0.53	22	3.42	1.15	5.98	9.81	7.43	4.90	8.95
Changes in Operating Assets and Liabilities, net	21	-0.11	72	-4.74	-2.58	47	84	5.10	-40	94
Net Cash From Investing Activities	-2.53	-1.12	-2.85	-2.21	-2.88	-3.41	-4.00	-3.50	-37	-2.92
Net Cash From Continuing Investing Activities	-2.53	-1.12	-2.85	-2.21	-2.88	-3.41	-4.00	-3.50	-37	-2.92
Purchase of Property, Plant & Equipment	-2.53	-1.12	-2.85	-2.21	-2.88	-3.43	-4.00	-3.68	-2.02	-2.92
Net Cash From Financing Activities	-4.08	-12	-15	-16	-6.42	-53	-115	-47	6.08	-108
Net Cash From Continuing Financing Activities	-4.08	-12	-15	-16	-6.42	-53	-115	-47	6.08	-108
Repayment of Debt	-0.35	-0.35	-3.15	-14	-56	-143	-316	-358	-407	-452
Repurchase of Common Equity	-4.08	-12	-15	-6.37	-6.40	-15	-4.72	-32	-11	-24
Issuance of Debt	0.35	0.35	3.15	14	56	112	206	347	424	376
Other Net Changes in Cash	-0.01	-	-	-	-	-	-	-0.00	-	-

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	589	681	950
Total Current Assets	335	417	677
Cash & Equivalents	82	17	3.60
Accounts Receivable	223	372	642
Prepaid Expenses	7.85	7.68	11
Current Deferred & Refundable Income Taxes	10	8.62	13
Other Current Assets	12	11	8.48
Plant, Property, & Equipment, net	29	27	20
Total Noncurrent Assets	225	237	253
Noncurrent Note & Lease Receivables	21	26	23
Goodwill	135	135	163
Intangible Assets	42	54	45
Noncurrent Deferred & Refundable Income Taxes	8.10	5.98	7.12
Other Noncurrent Operating Assets	19	15	14
Total Liabilities & Shareholders' Equity	589	681	950
Total Liabilities	170	213	498
Total Current Liabilities	120	156	279
Short-Term Debt	4.41	6.79	7.50
Accounts Payable	65	93	193
Current Employee Benefit Liabilities	48	52	73
Other Current Liabilities	3.40	4.16	6.03
Total Noncurrent Liabilities	50	57	70
Noncurrent Deferred & Payable Income Tax Liabilities	10	11	7.65
Other Noncurrent Operating Liabilities	40	47	63
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	419	468	451
Total Preferred & Common Equity	419	468	451
Total Common Equity	419	468	451
Common Stock	202	236	293
Retained Earnings	218	233	160
Accumulated Other Comprehensive Income / (Loss)	-1.44	-1.39	-1.39

This table presents Cross Country Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	597	603	648	708	771	921	883
Total Current Assets	337	338	387	445	506	649	660
Cash & Equivalents	64	70	5.24	14	0.67	0.29	30
Accounts Receivable	245	242	357	410	485	627	611
Prepaid Expenses	4.55	6.25	7.62	4.78	6.75	11	3.95
Current Deferred & Refundable Income Taxes	10	8.97	6.33	5.24	4.13	1.78	-
Other Current Assets	13	11	11	11	9.20	8.53	15
Plant, Property, & Equipment, net	29	29	28	26	25	23	19
Total Noncurrent Assets	232	236	233	236	241	249	204
Noncurrent Note & Lease Receivables	22	23	23	22	22	23	21
Goodwill	135	135	135	135	137	142	113
Intangible Assets	46	49	52	57	60	63	47
Noncurrent Deferred & Refundable Income Taxes	9.04	10	6.81	6.53	7.62	7.71	8.79
Other Noncurrent Operating Assets	19	18	16	15	14	14	14
Total Liabilities & Shareholders' Equity	597	603	648	708	771	921	883
Total Liabilities	173	164	180	238	301	469	460
Total Current Liabilities	121	110	128	184	216	265	277
Short-Term Debt	4.10	4.10	4.10	6.91	16	13	7.50
Accounts Payable	58	56	69	115	140	177	192
Current Employee Benefit Liabilities	54	47	52	57	56	70	71
Other Current Liabilities	3.86	3.72	3.82	4.45	4.65	5.84	6.29
Total Noncurrent Liabilities	52	54	52	55	85	204	183
Capital Lease Obligations	2.35	-	-	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	11	12	11	9.91	9.19	8.43	0.24
Other Noncurrent Operating Liabilities	39	42	40	45	45	57	53
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	425	439	468	470	470	452	423
Total Preferred & Common Equity	425	439	468	470	470	452	423
Total Common Equity	425	439	468	470	470	452	423
Common Stock	204	215	229	242	255	258	297
Retained Earnings	222	225	241	229	217	195	127
Accumulated Other Comprehensive Income / (Loss)	-1.40	-1.39	-1.39	-1.39	-1.38	-1.38	-1.37

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-33.46%	-27.95%	67.20%
EBITDA Growth	-98.52%	-53.85%	89.28%
EBIT Growth	-114.44%	-58.47%	93.62%
NOPAT Growth	-114.84%	-59.88%	43.66%
Net Income Growth	-120.04%	-60.95%	40.89%
EPS Growth	-121.46%	-58.59%	40.23%
Operating Cash Flow Growth	-51.66%	85.38%	256.57%
Free Cash Flow Firm Growth	-54.13%	187.42%	157.33%
Invested Capital Growth	-25.28%	-24.29%	24.68%
Revenue Q/Q Growth	-7.19%	-9.59%	-0.56%
EBITDA Q/Q Growth	-90.24%	-21.98%	-8.76%
EBIT Q/Q Growth	-1,149.71%	-25.33%	-9.26%
NOPAT Q/Q Growth	-40,650.06%	-29.75%	-16.93%
Net Income Q/Q Growth	-724.70%	-29.06%	-18.16%
EPS Q/Q Growth	-1,366.67%	-27.56%	-17.91%
Operating Cash Flow Q/Q Growth	11.26%	3.22%	137.82%
Free Cash Flow Firm Q/Q Growth	9.06%	25.29%	127.28%
Invested Capital Q/Q Growth	-6.91%	-1.06%	14.06%
Profitability Metrics	-	-	-
Gross Margin	98.41%	99.28%	99.66%
EBITDA Margin	0.14%	6.48%	10.12%
Operating Margin	-1.25%	5.58%	9.63%
EBIT Margin	-1.21%	5.58%	9.67%
Profit (Net Income) Margin	-1.08%	3.60%	6.63%
Tax Burden Percent	88.77%	70.59%	73.48%
Interest Burden Percent	100.85%	91.36%	93.32%
Effective Tax Rate	0.00%	29.41%	26.52%
Return on Invested Capital (ROIC)	-2.95%	14.99%	36.43%
ROIC Less NNEP Spread (ROIC-NNEP)	3.33%	5.25%	29.17%
Return on Net Nonoperating Assets (RNNOA)	-0.33%	0.81%	13.23%
Return on Equity (ROE)	-3.28%	15.80%	49.66%
Cash Return on Invested Capital (CROIC)	25.98%	42.64%	14.47%
Operating Return on Assets (OROA)	-2.56%	13.81%	32.24%
Return on Assets (ROA)	-2.29%	8.91%	22.11%
Return on Common Equity (ROCE)	-3.28%	15.80%	49.66%
Return on Equity Simple (ROE_SIMPLE)	-3.47%	15.53%	41.19%
Net Operating Profit after Tax (NOPAT)	-12	80	198
NOPAT Margin	-0.88%	3.94%	7.07%
Net Nonoperating Expense Percent (NNEP)	-6.29%	9.74%	7.26%
Return On Investment Capital (ROIC_SIMPLE)	-2.79%	16.77%	43.21%
Cost of Revenue to Revenue	1.59%	0.72%	0.34%
SG&A Expenses to Revenue	17.36%	14.87%	11.56%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	99.66%	93.70%	90.03%
Earnings before Interest and Taxes (EBIT)	-16	113	271
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.94	131	284
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.43	1.70	2.19
Price to Tangible Book Value (P/TBV)	2.47	2.87	4.07
Price to Revenue (P/Rev)	0.44	0.39	0.35
Price to Earnings (P/E)	0.00	10.96	5.33
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	9.13%	18.77%
Enterprise Value to Invested Capital (EV/IC)	1.52	1.72	1.65
Enterprise Value to Revenue (EV/Rev)	0.39	0.39	0.35
Enterprise Value to EBITDA (EV/EBITDA)	268.32	6.00	3.51
Enterprise Value to EBIT (EV/EBIT)	0.00	6.97	3.67
Enterprise Value to NOPAT (EV/NOPAT)	0.00	9.87	5.02
Enterprise Value to Operating Cash Flow (EV/OCF)	4.33	3.16	7.42
Enterprise Value to Free Cash Flow (EV/FCFF)	5.01	3.47	12.63
Leverage & Solvency	-	-	-
Debt to Equity	0.01	0.01	0.02
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.10	0.15	0.45
Leverage Ratio	1.43	1.77	2.25
Compound Leverage Factor	1.44	1.62	2.10
Debt to Total Capital	1.04%	1.43%	1.63%
Short-Term Debt to Total Capital	1.04%	1.43%	1.63%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.96%	98.57%	98.37%
Debt to EBITDA	2.27	0.05	0.03
Net Debt to EBITDA	-39.81	-0.08	0.01
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	-0.37	0.09	0.04
Net Debt to NOPAT	6.54	-0.13	0.02
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.25	6.69	5.83
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.78	2.67	2.43
Quick Ratio	2.53	2.50	2.31
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	104	226	79
Operating Cash Flow to CapEx	1,378.43%	1,778.29%	1,525.72%
Free Cash Flow to Firm to Interest Expense	47.44	23.05	4.35
Operating Cash Flow to Interest Expense	54.90	25.31	7.40
Operating Cash Flow Less CapEx to Interest Expense	50.92	23.89	6.91
Efficiency Ratios	-	-	-
Asset Turnover	2.12	2.48	3.33
Accounts Receivable Turnover	4.51	3.98	4.94
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	47.84	85.94	157.96
Accounts Payable Turnover	0.27	0.10	0.06
Days Sales Outstanding (DSO)	80.87	91.62	73.92
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,343.44	3,582.05	5,749.99
Cash Conversion Cycle (CCC)	-1,262.57	-3,490.43	-5,676.07
Capital & Investment Metrics	-	-	-
Invested Capital	342	457	604
Invested Capital Turnover	3.36	3.81	5.15
Increase / (Decrease) in Invested Capital	-116	-147	120
Enterprise Value (EV)	521	786	995
Market Capitalization	598	796	991
Book Value per Share	$12.73	$13.30	$12.11
Tangible Book Value per Share	$7.34	$7.90	$6.53
Total Capital	423	474	459
Total Debt	4.41	6.79	7.50
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-77	-10	3.90
Capital Expenditures (CapEx)	8.71	14	8.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)	137	250	402
Debt-free Net Working Capital (DFNWC)	219	268	406
Net Working Capital (NWC)	215	261	398
Net Nonoperating Expense (NNE)	2.75	6.93	12
Net Nonoperating Obligations (NNO)	-77	-10	153
Total Depreciation and Amortization (D&A)	18	18	13
Debt-free, Cash-free Net Working Capital to Revenue	10.22%	12.40%	14.35%
Debt-free Net Working Capital to Revenue	16.30%	13.25%	14.47%
Net Working Capital to Revenue	15.97%	12.91%	14.21%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.44)	$2.07	$5.09
Adjusted Weighted Average Basic Shares Outstanding	33.38M	35.16M	37.01M
Adjusted Diluted Earnings per Share	($0.44)	$2.05	$5.02
Adjusted Weighted Average Diluted Shares Outstanding	33.38M	35.48M	37.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.81M	34.73M	36.82M
Normalized Net Operating Profit after Tax (NOPAT)	-3.80	82	204
Normalized NOPAT Margin	-0.28%	4.06%	7.27%
Pre Tax Income Margin	-1.22%	5.09%	9.03%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-7.43	11.47	14.97
NOPAT to Interest Expense	-5.40	8.10	10.95
EBIT Less CapEx to Interest Expense	-11.41	10.05	14.48
NOPAT Less CapEx to Interest Expense	-9.38	6.68	10.46
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-256.32%	79.38%	18.97%

This table displays calculated financial ratios and metrics derived from Cross Country Healthcare's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-25.14%	-28.75%	-37.16%	-39.11%	-33.75%	-30.47%	-28.25%	-21.05%	-2.45%	69.67%
EBITDA Growth	-99.49%	-70.33%	-136.04%	-81.95%	-65.22%	-55.42%	-52.51%	-47.82%	-34.54%	87.84%
EBIT Growth	-131.53%	-85.96%	-153.99%	-90.52%	-72.18%	-61.37%	-55.98%	-51.67%	-36.36%	94.62%
NOPAT Growth	-125.69%	-83.88%	-154.25%	-93.37%	-76.97%	-64.21%	-55.93%	-50.17%	-49.47%	48.19%
Net Income Growth	-141.52%	-80.06%	-175.19%	-90.85%	-75.11%	-63.18%	-59.65%	-52.51%	-53.19%	48.48%
EPS Growth	-146.43%	-77.78%	-178.33%	-90.12%	-71.72%	-61.29%	-57.14%	-50.31%	-52.17%	50.00%
Operating Cash Flow Growth	100.71%	-89.38%	-30.90%	-87.17%	179.49%	-50.00%	557.34%	261.39%	105.89%	5,067.40%
Free Cash Flow Firm Growth	-27.48%	20.55%	-1.71%	967.79%	297.72%	148.38%	147.22%	104.91%	59.51%	-68.71%
Invested Capital Growth	-25.28%	-20.58%	-27.67%	-22.49%	-24.29%	-12.72%	-17.15%	3.30%	24.68%	62.69%
Revenue Q/Q Growth	-1.64%	-7.26%	-10.39%	-8.42%	-6.39%	-18.20%	-13.17%	-0.88%	-1.75%	-15.59%
EBITDA Q/Q Growth	-98.74%	151.35%	-262.35%	-51.22%	-27.35%	-37.63%	-18.69%	-11.18%	-6.88%	-33.56%
EBIT Q/Q Growth	-250.04%	114.91%	-557.58%	-69.38%	-33.16%	-42.68%	-19.70%	-15.23%	-7.20%	-34.68%
NOPAT Q/Q Growth	-211.73%	116.00%	-730.72%	-77.21%	-29.87%	-46.18%	-22.87%	-25.39%	8.98%	-33.72%
Net Income Q/Q Growth	-246.89%	115.92%	-696.21%	-70.21%	-29.46%	-39.98%	-27.49%	-24.12%	4.37%	-34.22%
EPS Q/Q Growth	-262.50%	117.02%	-687.50%	-71.43%	-22.22%	-40.00%	-25.93%	-23.58%	6.45%	-33.57%
Operating Cash Flow Q/Q Growth	224.42%	-90.93%	1,270.84%	-50.22%	-82.83%	-41.04%	154.45%	984.84%	-96.93%	675.19%
Free Cash Flow Firm Q/Q Growth	16.35%	-24.85%	-5.95%	-11.82%	93.41%	-38.72%	921.65%	115.68%	52.67%	40.20%
Invested Capital Q/Q Growth	-6.91%	-1.72%	-20.02%	0.85%	-1.06%	-10.50%	-14.29%	-1.19%	14.06%	-15.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.07%	99.52%	94.45%	99.66%	98.99%	99.47%	99.42%	99.21%	192.32%	99.83%
EBITDA Margin	0.03%	2.33%	-4.20%	2.32%	4.33%	5.59%	7.33%	7.82%	8.26%	8.71%
Operating Margin	-1.11%	0.91%	-5.65%	0.77%	3.24%	4.59%	6.51%	7.03%	7.72%	8.20%
EBIT Margin	-1.37%	0.90%	-5.59%	1.09%	3.26%	4.56%	6.51%	7.04%	7.75%	8.21%
Profit (Net Income) Margin	-1.21%	0.81%	-4.72%	0.71%	2.18%	2.90%	3.95%	4.73%	5.81%	5.47%
Tax Burden Percent	95.89%	75.39%	82.05%	72.97%	69.69%	65.70%	70.43%	73.37%	84.21%	71.44%
Interest Burden Percent	92.12%	119.67%	102.99%	88.87%	96.23%	96.71%	86.15%	91.58%	89.02%	93.30%
Effective Tax Rate	0.00%	24.61%	0.00%	27.03%	30.31%	34.30%	29.57%	26.63%	15.79%	28.56%
Return on Invested Capital (ROIC)	-2.61%	2.38%	-14.01%	1.87%	8.60%	13.58%	19.53%	22.98%	33.47%	38.63%
ROIC Less NNEP Spread (ROIC-NNEP)	0.48%	1.14%	12.89%	2.62%	8.15%	12.52%	16.87%	21.55%	30.94%	36.33%
Return on Net Nonoperating Assets (RNNOA)	-0.05%	-0.08%	-0.27%	0.43%	1.26%	1.40%	4.95%	10.08%	14.03%	12.25%
Return on Equity (ROE)	-2.66%	2.30%	-14.28%	2.29%	9.86%	14.98%	24.48%	33.06%	47.50%	50.88%
Cash Return on Invested Capital (CROIC)	25.98%	22.95%	34.12%	34.62%	42.64%	36.42%	42.84%	25.18%	14.47%	8.10%
Operating Return on Assets (OROA)	-2.90%	1.99%	-12.82%	2.48%	8.06%	12.81%	18.47%	20.23%	25.83%	32.98%
Return on Assets (ROA)	-2.56%	1.80%	-10.83%	1.61%	5.41%	8.14%	11.21%	13.59%	19.36%	21.98%
Return on Common Equity (ROCE)	-2.66%	2.30%	-14.28%	2.29%	9.86%	14.98%	24.48%	33.06%	47.50%	50.88%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-0.42%	1.93%	9.80%	0.00%	21.80%	26.44%	34.50%	0.00%	53.76%
Net Operating Profit after Tax (NOPAT)	-2.40	2.15	-13	2.13	9.36	13	25	32	41	37
NOPAT Margin	-0.78%	0.68%	-3.96%	0.56%	2.26%	3.02%	4.58%	5.16%	6.50%	5.86%
Net Nonoperating Expense Percent (NNEP)	-3.08%	1.24%	-26.90%	-0.75%	0.45%	1.06%	2.66%	1.43%	2.54%	2.30%
Return On Investment Capital (ROIC_SIMPLE)	-0.57%	-	-	-	1.97%	-	-	-	8.85%	-
Cost of Revenue to Revenue	-0.07%	0.48%	5.55%	0.34%	1.01%	0.53%	0.58%	0.79%	-92.32%	0.17%
SG&A Expenses to Revenue	17.93%	17.23%	17.73%	16.68%	16.30%	15.74%	14.60%	13.53%	12.90%	12.69%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	101.18%	98.61%	100.10%	98.89%	95.75%	94.88%	92.91%	92.18%	184.61%	91.62%
Earnings before Interest and Taxes (EBIT)	-4.25	2.83	-19	4.15	13	20	35	44	48	52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.09	7.33	-14	8.79	18	25	40	49	52	55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.43	1.07	1.10	1.41	1.70	1.89	2.15	1.82	2.19	2.57
Price to Tangible Book Value (P/TBV)	2.47	1.87	1.89	2.34	2.87	3.20	3.69	3.32	4.07	4.13
Price to Revenue (P/Rev)	0.44	0.31	0.31	0.37	0.39	0.40	0.42	0.31	0.35	0.38
Price to Earnings (P/E)	0.00	0.00	56.67	14.34	10.96	8.67	8.11	5.27	5.33	4.77
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.76%	6.97%	9.13%	11.54%	12.33%	18.97%	18.77%	20.95%
Enterprise Value to Invested Capital (EV/IC)	1.52	1.08	1.11	1.41	1.72	1.90	2.04	1.61	1.65	2.25
Enterprise Value to Revenue (EV/Rev)	0.39	0.27	0.26	0.37	0.39	0.39	0.43	0.37	0.35	0.42
Enterprise Value to EBITDA (EV/EBITDA)	268.32	19.96	11.16	7.21	6.00	5.24	5.31	4.01	3.51	3.83
Enterprise Value to EBIT (EV/EBIT)	0.00	256.17	22.02	8.99	6.97	5.84	5.77	4.27	3.67	3.99
Enterprise Value to NOPAT (EV/NOPAT)	0.00	13,629.97	46.59	13.24	9.87	7.77	7.69	5.77	5.02	4.99
Enterprise Value to Operating Cash Flow (EV/OCF)	4.33	3.68	2.43	3.16	3.16	3.66	3.39	4.63	7.42	21.14
Enterprise Value to Free Cash Flow (EV/FCFF)	5.01	4.17	2.74	3.55	3.47	4.87	4.32	6.51	12.63	34.39
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.02	0.01	0.01	0.01	0.01	0.10	0.33	0.02	0.32
Long-Term Debt to Equity	0.00	0.01	0.00	0.00	0.00	0.00	0.07	0.31	0.00	0.31
Financial Leverage	-0.10	-0.07	-0.02	0.16	0.15	0.11	0.29	0.47	0.45	0.34
Leverage Ratio	1.43	1.46	1.51	1.71	1.77	1.78	1.94	2.27	2.25	2.19
Compound Leverage Factor	1.32	1.75	1.56	1.52	1.71	1.72	1.67	2.08	2.00	2.05
Debt to Total Capital	1.04%	1.50%	0.93%	0.87%	1.43%	1.45%	9.05%	25.04%	1.63%	24.51%
Short-Term Debt to Total Capital	1.04%	0.95%	0.93%	0.87%	1.43%	1.45%	3.06%	2.07%	1.63%	1.34%
Long-Term Debt to Total Capital	0.00%	0.54%	0.00%	0.00%	0.00%	0.00%	5.99%	22.96%	0.00%	23.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.96%	98.50%	99.07%	99.13%	98.57%	98.55%	90.95%	74.96%	98.37%	75.49%
Debt to EBITDA	2.27	0.32	0.11	0.05	0.05	0.04	0.24	0.62	0.03	0.44
Net Debt to EBITDA	-39.81	-2.90	-1.76	-0.01	-0.08	-0.04	0.23	0.62	0.01	0.34
Long-Term Debt to EBITDA	0.00	0.12	0.00	0.00	0.00	0.00	0.16	0.57	0.00	0.42
Debt to NOPAT	-0.37	221.48	0.46	0.08	0.09	0.06	0.34	0.90	0.04	0.57
Net Debt to NOPAT	6.54	-1,977.54	-7.34	-0.02	-0.13	-0.07	0.34	0.89	0.02	0.45
Long-Term Debt to NOPAT	0.00	80.65	0.00	0.00	0.00	0.00	0.23	0.82	0.00	0.54
Altman Z-Score	5.32	4.97	5.25	5.95	6.21	6.38	6.16	4.87	5.05	5.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.78	2.79	3.07	3.02	2.67	2.43	2.34	2.45	2.43	2.38
Quick Ratio	2.53	2.56	2.83	2.82	2.50	2.31	2.25	2.37	2.31	2.32
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	113	97	129	138	156	81	132	13	-79	-167
Operating Cash Flow to CapEx	957.49%	664.59%	2,892.28%	271.99%	419.97%	2,052.88%	2,984.18%	1,274.20%	213.54%	4,824.25%
Free Cash Flow to Firm to Interest Expense	186.20	176.91	227.94	297.98	266.40	120.65	27.04	3.49	-14.81	-47.69
Operating Cash Flow to Interest Expense	39.86	13.58	145.07	13.01	20.60	105.10	24.48	12.70	0.81	40.20
Operating Cash Flow Less CapEx to Interest Expense	35.70	11.54	140.06	8.23	15.70	99.98	23.66	11.70	0.43	39.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.12	2.22	2.29	2.26	2.48	2.81	2.84	2.87	3.33	4.02
Accounts Receivable Turnover	4.51	4.42	4.33	3.61	3.98	4.37	4.09	4.05	4.94	6.18
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	47.84	52.43	58.48	69.27	85.94	99.69	112.69	132.73	157.96	168.64
Accounts Payable Turnover	0.27	18.25	16.20	12.74	0.10	10.45	9.72	12.79	0.06	14.23
Days Sales Outstanding (DSO)	80.87	82.59	84.25	101.16	91.62	83.43	89.22	90.16	73.92	59.04
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,343.44	20.00	22.53	28.65	3,582.05	34.94	37.53	28.54	5,749.99	25.65
Cash Conversion Cycle (CCC)	-1,262.57	62.59	61.72	72.51	-3,490.43	48.49	51.68	61.62	-5,676.07	33.39
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	342	367	374	467	457	462	516	603	604	530
Invested Capital Turnover	3.36	3.49	3.54	3.32	3.81	4.50	4.26	4.45	5.15	6.59
Increase / (Decrease) in Invested Capital	-116	-95	-143	-136	-147	-67	-107	19	120	204
Enterprise Value (EV)	521	397	416	657	786	880	1,055	972	995	1,192
Market Capitalization	598	454	481	658	796	888	1,009	822	991	1,085
Book Value per Share	$12.73	$12.56	$12.63	$13.68	$13.30	$13.12	$13.09	$12.27	$12.11	$11.06
Tangible Book Value per Share	$7.34	$7.18	$7.32	$8.21	$7.90	$7.74	$7.60	$6.72	$6.53	$6.87
Total Capital	423	431	443	472	474	477	517	603	459	560
Total Debt	4.41	6.45	4.10	4.10	6.79	6.91	47	151	7.50	137
Total Long-Term Debt	0.00	2.35	0.00	0.00	0.00	0.00	31	138	0.00	130
Net Debt	-77	-58	-66	-1.14	-10	-7.39	46	151	3.90	107
Capital Expenditures (CapEx)	2.53	1.12	2.85	2.21	2.88	3.43	4.00	3.68	2.02	2.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	137	156	162	258	250	254	305	396	402	360
Debt-free Net Working Capital (DFNWC)	219	220	232	263	268	269	305	396	406	391
Net Working Capital (NWC)	215	216	228	259	261	262	290	384	398	383
Net Nonoperating Expense (NNE)	1.35	-0.40	2.61	-0.56	0.32	0.53	3.44	2.70	4.31	2.48
Net Nonoperating Obligations (NNO)	-77	-58	-66	-1.14	-10	-7.39	46	151	153	107
Total Depreciation and Amortization (D&A)	4.34	4.50	4.72	4.64	4.47	4.54	4.43	4.90	3.16	3.21
Debt-free, Cash-free Net Working Capital to Revenue	10.22%	10.77%	10.29%	14.51%	12.40%	11.38%	12.55%	14.99%	14.35%	12.78%
Debt-free Net Working Capital to Revenue	16.30%	15.19%	14.71%	14.81%	13.25%	12.02%	12.58%	15.00%	14.47%	13.86%
Net Working Capital to Revenue	15.97%	14.91%	14.45%	14.57%	12.91%	11.71%	11.93%	14.53%	14.21%	13.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	$0.08	($0.47)	$0.08	$0.28	$0.37	$0.60	$0.82	$1.00	$0.94
Adjusted Weighted Average Basic Shares Outstanding	33.38M	33.02M	33.96M	34.22M	35.16M	34.95M	35.35M	35.86M	37.01M	37.10M
Adjusted Diluted Earnings per Share	($0.13)	$0.08	($0.47)	$0.08	$0.28	$0.36	$0.60	$0.81	$0.99	$0.93
Adjusted Weighted Average Diluted Shares Outstanding	33.38M	33.06M	33.96M	34.60M	35.48M	35.15M	35.52M	36.56M	37.54M	37.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	32.81M	32.92M	33.81M	34.77M	34.73M	35.15M	35.80M	35.93M	36.82M	37.30M
Normalized Net Operating Profit after Tax (NOPAT)	2.27	2.90	-12	3.26	10.00	14	26	32	41	42
Normalized NOPAT Margin	0.73%	0.92%	-3.50%	0.86%	2.41%	3.10%	4.77%	5.21%	6.50%	6.57%
Pre Tax Income Margin	-1.26%	1.08%	-5.76%	0.97%	3.13%	4.41%	5.61%	6.44%	6.90%	7.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.99	5.15	-33.44	8.98	23.00	30.14	7.22	11.87	9.09	14.92
NOPAT to Interest Expense	-3.95	3.91	-23.67	4.61	15.96	19.94	5.09	8.71	7.62	10.66
EBIT Less CapEx to Interest Expense	-11.15	3.11	-38.46	4.20	18.09	25.02	6.40	10.88	8.71	14.09
NOPAT Less CapEx to Interest Expense	-8.12	1.87	-28.69	-0.17	11.06	14.82	4.27	7.71	7.24	9.82
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-256.32%	-2,245.67%	500.28%	70.31%	79.38%	60.74%	57.71%	43.00%	18.97%	10.71%

Frequently Asked Questions About Cross Country Healthcare's Financials

When does Cross Country Healthcare's financial year end?

According to the most recent income statement we have on file, Cross Country Healthcare's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Cross Country Healthcare's net income changed over the last 2 years?

Cross Country Healthcare's net income appears to be on a downward trend, with a most recent value of -$14.56 million in 2024, falling from $185.98 million in 2022. The previous period was $72.63 million in 2023. Check out Cross Country Healthcare's forecast to explore projected trends and price targets.

What is Cross Country Healthcare's operating income?

Cross Country Healthcare's total operating income in 2024 was -$16.87 million, based on the following breakdown:

Total Gross Profit: $1.32 billion
Total Operating Expenses: $1.34 billion

How has Cross Country Healthcare revenue changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's total revenue changed from $2.80 billion in 2022 to $1.34 billion in 2024, a change of -52.1%.

How much debt does Cross Country Healthcare have?

Cross Country Healthcare's total liabilities were at $170.29 million at the end of 2024, a 20.2% decrease from 2023, and a 65.8% decrease since 2022.

How much cash does Cross Country Healthcare have?

In the past 2 years, Cross Country Healthcare's cash and equivalents has ranged from $3.60 million in 2022 to $81.63 million in 2024, and is currently $81.63 million as of their latest financial filing in 2024.

How has Cross Country Healthcare's book value per share changed over the last 2 years?

Over the last 2 years, Cross Country Healthcare's book value per share changed from 12.11 in 2022 to 12.73 in 2024, a change of 5.1%.

Related Companies

This page (NASDAQ:CCRN) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cross Country Healthcare (CCRN) Financials

Frequently Asked Questions About Cross Country Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cross Country Healthcare (CCRN) Financials

Annual Income Statements for Cross Country Healthcare

Quarterly Income Statements for Cross Country Healthcare

Annual Cash Flow Statements for Cross Country Healthcare

Quarterly Cash Flow Statements for Cross Country Healthcare

Annual Balance Sheets for Cross Country Healthcare

Quarterly Balance Sheets for Cross Country Healthcare

Annual Metrics And Ratios for Cross Country Healthcare

Quarterly Metrics And Ratios for Cross Country Healthcare

Frequently Asked Questions About Cross Country Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools